Taurine

Phase 1Small molecule

TThird Military Medical University

Taurine is one of 143 small molecule programs targeting Oxidative Stress. It is currently in Phase 1.

Indications

Total Trials

Active Trials

142

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oxidative StressActive, not recruiting

PsychosisActive, not recruiting

Peripartum CardiomyopathyActive, not recruiting

CataractActive, not recruiting

Bipolar DisorderActive, not recruiting

Long COVIDNot yet recruiting

Oxidative StressPhase 1/Phase 2

Active, not recruiting

PsychosisPhase 2/Phase 3

Active, not recruiting

Peripartum CardiomyopathyPhase 2/Phase 3

Active, not recruiting

CataractPhase 1/Phase 2

Active, not recruiting

Bipolar DisorderPhase 1

Active, not recruiting

Long COVIDPreclinical

Not yet recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Phase 3

1 2

Lotemax

BBausch & Lomb Incorporated

Phase 3

7 3

Kenalog

BBausch Health Americas, Inc.

Phase 3

4 4

Avastin

BBio-Thera Solutions

Phase 3

1 5

Aquasol E

NNational Eye Institute (NEI)

Mapracorat

4 7

Ripasudil

KKowa Research Institute, Inc.

Phase 3

2 8

Taurine

TThird Military Medical University

Phase 1

1 9

Zolymbus

AbbVie

Preclinical

—10

Neurontin

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2/3Recruiting

Long COVID

NCT06721949

PreclinicalNot yet recruiting

Long COVID

NCT07682402

Clinical

Trials by Indication[1]

Long COVID2 trials

Taurine Supplementation in Long COVID

Recruiting·UUniversity of Alberta·Phase 2/3·NCT06721949·300 enrolled

An Open-Label Study of Taurine Supplementation in Adolescents With Post-COVID Condition: Quantifying Taurine Plasma Levels and Evaluating Clinical and Biological Outcomes

Not yet recruiting·UUniversity of Alberta·Preclinical·NCT07682402·30 enrolled

Cognitive Function1 trial

Taurine Supplementation on Cognitive Function in Patients With Diabetes

Unknown status·TThird Military Medical University·N/A·NCT03410173·200 enrolled

Oxidative Stress1 trial

Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine

Completed·UUniversity of Colorado, Denver·Phase 1/2·NCT01192828·15 enrolled

Bipolar Disorder1 trial

Taurine in Adolescents With Bipolar Disorder

Terminated·CCambridge Health Alliance·Phase 1·NCT00391001·4 enrolled

MPA1 trial

Impact of Energy Drinks on the Manual Dexterity of Final Year Dental Students

Completed·RRiyadh Colleges of Dentistry and Pharmacy·Phase 4·NCT02535143·60 enrolled

6 more indications

Double-blind1 trial

Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study

Completed·MMclean Hospital·Phase 2·NCT00217165·60 enrolled

Cataract1 trial

Taurine Eye Drops May Prevent the Progression of Cataract

Active, not recruiting·UUniversity Of Anbar·Phase 1/2·NCT06639711·50 enrolled

Peripartum Cardiomyopathy1 trial

Taurine in Peripartum Cardiomyopathy

Completed·—·Phase 2/3·NCT03907267·40 enrolled

Psychosis1 trial

A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment

Completed·MMelbourne Health·Phase 2/3·NCT00420823·121 enrolled

Extremity1 trial

Taurine Supplementation on Lower Extremity Vasculopathy in Patients With Diabetes

Unknown status·TThird Military Medical University·N/A·NCT03410537·200 enrolled

Unspecified2 trials

Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients

Unknown status·HHamad Medical Corporation·Phase 1/2·NCT01226537·20 enrolled

Effect of Amnion Membrane With and Without Taurine on GCF TNF α Level.

Completed·MMaharishi Markendeswar University (Deemed to be University)·N/A·NCT04772508·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Taurine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Taurine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Taurine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Third Military Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TThird Military Medical University

Taurine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Long COVID2 trials

Cognitive Function1 trial

Oxidative Stress1 trial

Bipolar Disorder1 trial

MPA1 trial

Double-blind1 trial

Cataract1 trial

Peripartum Cardiomyopathy1 trial

Psychosis1 trial

Extremity1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News